# AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
Canonical URL: https://biopharmsignal.com/news/ANGO/angiodynamics-announces-two-year-preserve-trial-data-demonstrating-durable-nanoknife-ire-system-outcomes-in-intermediate-risk-prostate-cancer
Ticker: ANGO
Company: AngioDynamics
Source: AngioDynamics
Published: 2026-05-13 13:00 EST
Original Source URL: https://investors.angiodynamics.com
## Summary

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system,

## Article Body
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system,
## Recent Company News
- 2026-05-28 17:25 EST — [AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect](https://biopharmsignal.com/news/ANGO/angiodynamics-expands-patient-access-to-nanoknife-ire-for-prostate-and-liver-cancer-as-medicare-coverage-framework-takes-effect) — Source: AngioDynamics
- 2026-05-27 12:30 EST — [AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: AngioDynamics
- 2026-05-13 13:00 EST — [AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer](https://biopharmsignal.com/news/ANGO/angiodynamics-announces-two-year-preserve-trial-data-demonstrating-durable-nanoknife-ire-system-outcomes-in-intermediate-risk-prostate-cancer) — Source: AngioDynamics
- 2026-04-02 10:00 EST — [AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability](https://biopharmsignal.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability) — Source: AngioDynamics
- 2026-03-31 12:00 EST — [AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: AngioDynamics
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)